Venous Ulcers and Hyaluronic Acid Phonophoresis
Enhancing Venous Ulcer Healing Via Hyaluronic Acid Phonophoresis: A Randomized Controlled Clinical Trial
1 other identifier
interventional
64
1 country
1
Brief Summary
Venous leg ulcers are severe manifestations of chronic venous insufficiency and account for a large proportion of lower limb ulcers. They typically occur below the knee, persist for more than six weeks, and are associated with significant impairment in quality of life and substantial socioeconomic burden. A major clinical challenge is their high recurrence rate, which can reach 50-70% within six months, making treatment resource-intensive and requiring multidisciplinary care. Therapeutic ultrasound and phonophoresis have been proposed to enhance wound healing by promoting tissue repair and improving transdermal drug delivery, including hyaluronic acid, which supports extracellular matrix restoration and wound healing. However, despite the theoretical advantages of combining ultrasound with hyaluronic acid, robust clinical evidence for its effectiveness in venous leg ulcers remains limited. The study aimed to assess the effect of ultrasound-enhanced hyaluronic acid delivery on venous ulcer healing compared to ultrasound followed by topical application of hyaluronic acid.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 26, 2025
CompletedFirst Submitted
Initial submission to the registry
May 31, 2026
CompletedFirst Posted
Study publicly available on registry
June 4, 2026
CompletedJune 4, 2026
May 1, 2026
2 months
May 31, 2026
May 31, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage Wound Area Reduction (PWAR)
It is calculated as: \[(baseline wound area - post-treatment wound area) ÷ baseline wound area\] × 100. Digital wound measurements were obtained at baseline and at week four using the validated imitoMeasure smartphone application (imito AG, Zurich, Switzerland). Standardized image acquisition procedures were followed, with the smartphone camera positioned 20-30 cm from the wound and maintained parallel to the wound surface. A calibration marker (QR code) was placed adjacent to the wound on the same plane before image capture, and a photo was taken once the app recognized the QR code. The operator delineated the wound borders on the photo using their finger then the app generated measurements of area, width, length, and circumference.
After 3 sessions per week for 4 weeks
Secondary Outcomes (1)
Rate of Healing
After 3 sessions per week for 4 weeks
Study Arms (2)
Study Group A
EXPERIMENTALThis group included 32 patients with venous ulcers who received combined treatment of topical hyaluronic acid gel and therapeutic ultrasound therapy, three sessions weekly for four weeks, in addition to the traditional physical therapy management including compression therapy and active ankle exercises.
Study Group B
EXPERIMENTALThis group included 32 patients with venous ulcers who received ultrasound first then followed by topical hyaluronic acid, three sessions weekly for four weeks in addition to the traditional physical therapy management including compression therapy and active ankle exercises.
Interventions
For Study Group (A): A layer of 0.2% topical hyaluronic acid gel was applied to cover and fill the wound cavity . A sterile glove filled with ultrasound gel was, then secured to the wound with surgical plaster, and ultrasound therapy was applied concurrently. The ultrasound was delivered for 1 minute per 1 cm² of the wound. The parameters used were 0.5 W/cm², low intensity, 1 MHz frequency, and pulsed mode with a 20% duty cycle, adjusted based on the ulcer size. The gel was removed, and the wound was dried and cleaned with saline and the US head with alcohol after each session. The treatment period lasted 4 weeks, with three sessions per week.
Pulsed TUS was applied to the wound area at identical parameters to Group A (0.5 W/cm², 1 MHz, 20% duty cycle, one minute per cm²). Immediately following the TUS session, 0.2% HA gel was applied topically to the wound surface. Standard wound care was delivered as described for Group A. Treatment frequency and duration were identical to Group A.
Eligibility Criteria
You may qualify if:
- Patients of both genders whose ages were between 30 - 70 years.
- Patients with active venous ulcers (C6) according to CEAP (Clinical manifestations- Etiology- Anatomic distribution-Pathophysiology) classification.
- clinically proved to be non-infected venous ulcers.
- Patients receive the traditional physical therapy management for venous ulcers which includes compression therapy and active exercise plus frequent dressing change.
- Patients suffering from recurrent or failed to heal venous ulcers.
You may not qualify if:
- Individuals who were confined to bed with life-threatening conditions that could interfere with the study's objectives, such as myocardial infarction, renal failure or autoimmune diseases.
- Patients who had hyaluronic acid hypersensitivity.
- Presence of skin disorders or conditions that considered contraindicated for therapeutic US (e.g., cellulitis).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Outpatient Clinics of Faculty of Physical Therapy ,Cairo University.
Giza, Egypt
Related Publications (5)
https://www.mdpi.com/2077-0383/11/3/537
BACKGROUNDhttps://www.mdpi.com/2073-4409/11/15/2439
BACKGROUNDAlkahtani SA, Kunwar PS, Jalilifar M, Rashidi S, Yadollahpour A. Ultrasound-based Techniques as Alternative Treatments for Chronic Wounds: A Comprehensive Review of Clinical Applications. Cureus. 2017 Dec 15;9(12):e1952. doi: 10.7759/cureus.1952.
PMID: 29487767BACKGROUNDBiagioni RB, Carvalho BV, Manzioni R, Matielo MF, Brochado Neto FC, Sacilotto R. Smartphone application for wound area measurement in clinical practice. J Vasc Surg Cases Innov Tech. 2021 Feb 26;7(2):258-261. doi: 10.1016/j.jvscit.2021.02.008. eCollection 2021 Jun.
PMID: 33997567BACKGROUNDRaffetto JD, Ligi D, Maniscalco R, Khalil RA, Mannello F. Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment. J Clin Med. 2020 Dec 24;10(1):29. doi: 10.3390/jcm10010029.
PMID: 33374372BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
HESHAM GALAL MAHRAN, Professor of PT
Faculty of Physical Therapy, department of physical therapy for surgery, Cairo University, Egypt
- STUDY DIRECTOR
SHAIMAA MOHAMED ELSAYEH, Ass. Prof. of PT
Faculty of Physical Therapy, department of physical therapy for surgery, Cairo University, Egypt
- STUDY DIRECTOR
WALIED MOHAMED KHEREBA, Prof. vascular surgery
Faculty of medicine, department of vascular and endovascular surgery, AL-Azhar University New Damietta, Egypt
- STUDY DIRECTOR
Rasha S Farag, MSc
Damietta Directorate for Health Affairs
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Master of Physical Therapy for Surgery, Cairo University, Egypt
Study Record Dates
First Submitted
May 31, 2026
First Posted
June 4, 2026
Study Start
December 12, 2024
Primary Completion
February 20, 2025
Study Completion
February 26, 2025
Last Updated
June 4, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be publicly shared due to privacy and confidentiality considerations, in accordance with institutional and ethical committee regulations governing patient data protection.